Exchange: SIX Industry: Pharmaceuticals, Biotechnology & Life Sciences
0.58% CHF89.57
America/New_York / 2 mai 2024 @ 03:46
FUNDAMENTALS | |
---|---|
MarketCap: | 175 242 mill |
EPS: | 4.03 |
P/E: | 22.23 |
Earnings Date: | Jul 17, 2024 |
SharesOutstanding: | 1 956.49 mill |
Avg Daily Volume: | 3.27 mill |
RATING 2024-04-30 |
---|
S- |
Strong Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Strong Buy | |
Return On Asset: | Strong Buy | |
DE: | Strong Buy | |
P/E: | Buy | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.88x |
Company: PE 22.23 | sector: PE 25.29 |
PE RATIO: COMPANY / INDUSTRY |
---|
1.30x |
Company: PE 22.23 | industry: PE 17.08 |
DISCOUNTED CASH FLOW VALUE |
---|
CHF87.30 (-2.54%) CHF-2.27 |
Date: 2024-05-02 |
Expected Trading Range (DAY) |
---|
CHF 88.30 - 90.90 ( +/- 1.45%) |
ATR Model: 14 days |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | CHF89.57 (0.58% ) |
Volume | 0.350 mill |
Avg. Vol. | 3.27 mill |
% of Avg. Vol | 10.69 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.